Marcus Sundén, Sofia Norgren, Robert Lundqvist, Anne Andersson, Malin Sund, Oskar Hemmingsson
BACKGROUND: Breast cancer liver metastases (BCLM) is a common cause of breast cancer-related death. The prognostic and predictive value of receptor expression and St Gallen classification is challenged by receptor status discordance in distant metastases. The aim of this study was to determine the rate of receptor conversion from breast cancer to BCLM and the impact on survival. METHOD: Patients registered with BCLM in two Swedish national cancer registers were recruited retrospectively...
September 13, 2023: Breast Cancer Research: BCR
Joel S Parker, Michael Mullins, Maggie C U Cheang, Samuel Leung, David Voduc, Tammi Vickery, Sherri Davies, Christiane Fauron, Xiaping He, Zhiyuan Hu, John F Quackenbush, Inge J Stijleman, Juan Palazzo, J S Marron, Andrew B Nobel, Elaine Mardis, Torsten O Nielsen, Matthew J Ellis, Charles M Perou, Philip S Bernard
PURPOSE: To improve on current standards for breast cancer prognosis and prediction of chemotherapy benefit by developing a risk model that incorporates the gene expression-based "intrinsic" subtypes luminal A, luminal B, HER2-enriched, and basal-like. METHODS: A 50-gene subtype predictor was developed using microarray and quantitative reverse transcriptase polymerase chain reaction data from 189 prototype samples. Test sets from 761 patients (no systemic therapy) were evaluated for prognosis, and 133 patients were evaluated for prediction of pathologic complete response (pCR) to a taxane and anthracycline regimen...
September 10, 2023: Journal of Clinical Oncology
Çağlar Ünal, Tolga Özmen, Ahmet Serkan İlgün, Çetin Ordu, Enver Özkurt, Naziye Ak, Gül Alço, Zeynep Erdoğan İyigün, Sevgi Kurt, Tomris Duymaz, Mehmet Alper Öztürk, Filiz Elbüken Çelebi, Kanay Yararbaş, Gürsel Soybir, Fatma Aktepe, Vahit Özmen
BACKGROUND: The minichromosome maintenance protein-2 (MCM-2) is a more sensitive proliferation marker than Ki-67. This study aimed to evaluate the relationship between MCM-2 and Oncotype DX recurrence score (ODX-RS) and determine an MCM-2 cutoff value in high-risk patients according to TAILORx risk categorization. METHODS: Hormone receptor (HR) positive HER-2 negative early-stage breast cancer patients (pT1-2, pN0-N1, M0) who had ODX-RS were included in the study...
2023: Breast Cancer: Targets and Therapy
L Lukas Löfling, Nathalie C Støer, Bettina Kulle Andreassen, Giske Ursin, Edoardo Botteri
BACKGROUND: Previous studies assessed the prognostic effect of aspirin, statins, and metformin in breast cancer (BC) patients, with inconclusive results. METHODS: We performed a nationwide population-based cohort study to evaluate if post-diagnostic use of low-dose aspirin, statins, and metformin was associated with BC-specific survival. Women aged ≥ 50 years and diagnosed with BC in 2004-2017, who survived ≥ 12 months after diagnosis (follow-up started 12 months after diagnosis), were identified in the Cancer Registry of Norway...
August 30, 2023: Breast Cancer Research: BCR
Massimo Ferrucci, Francesco Milardi, Daniele Passeri, Luaya Fabrizio Mpungu, Andrea Francavilla, Matteo Cagol, Tania Saibene, Silvia Michieletto, Mariacristina Toffanin, Paola Del Bianco, Ugo Grossi, Alberto Marchet
BACKGROUND: Breast-conserving surgery (BCS) still remains a blind surgery despite all available tumor localization methods. Intraoperative ultrasound (IOUS) allows real-time visualization during all resection phases. METHODS: This was a prospective observational cohort study conducted at the Veneto Institute of Oncology between January 2021 and June 2022. Patients with ductal carcinoma in situ, T1-2 invasive cancer, or post-neoadjuvant tumors, suitable for BCS, were recruited...
October 2023: Annals of Surgical Oncology
Ismail Jatoi, Abeer M Shaaban, Eric Jou, John R Benson
No abstract text is available yet for this article.
August 2023: Current Problems in Surgery
Zhi Li, Ruipeng Zhao
AIM: To investigate the impacts of breast conservation therapy (BCT) and mastectomy on heart-specific mortality in breast cancer patients. METHODS: Patients with primary breast cancer registered in the Surveillance, Epidemiology, and End Results (SEER) database between Jan 1998 and Dec 2015 were included. Patients were divided into either breast conservation therapy or mastectomy group. To compare mortality caused by heart diseases in breast cancer patients with BCT or mastectomy, univariate and multivariate regression after propensity score matching (PSM) were performed...
August 12, 2023: BMC Surgery
Anna D Louie, Laura H Rosenberger
No abstract text is available yet for this article.
August 14, 2023: Annals of Surgical Oncology
Maissa Trabilsy, Arielle Roberts, Tahina Ahmed, Michael Silver, Donna Marie E Manasseh, Charusheela Andaz, Patrick I Borgen, Joshua A Feinberg
INTRODUCTION: The lack of racial diversity depicted in medical education texts may contribute to an implicit racial bias among clinicians. This bias influences outcomes, as familiarity with the various cutaneous manifestations of disease is essential to making an accurate diagnosis. To better understand the racial disparities in breast surgery, we sought to determine the extent of skin tone representation depicted in images of breast surgery and pathology textbooks. METHODS: Textbooks were screened for color images of conditions with sufficient skin tissue present to assign the Fitzpatrick skin phototype (FSP)...
August 8, 2023: Journal of Surgical Research
Holly J Pederson, Debra Pratt, Benjamin C Calhoun
No abstract text is available yet for this article.
July 3, 2023: Cleveland Clinic Journal of Medicine
Fernanda Mosele, Elise Deluche, Amelie Lusque, Loïc Le Bescond, Thomas Filleron, Yoann Pradat, Agnes Ducoulombier, Barbara Pistilli, Thomas Bachelot, Frederic Viret, Christelle Levy, Nicolas Signolle, Alexia Alfaro, Diep T N Tran, Ingrid Judith Garberis, Hugues Talbot, Stergios Christodoulidis, Maria Vakalopoulou, Nathalie Droin, Aurelie Stourm, Maki Kobayashi, Tomoya Kakegawa, Ludovic Lacroix, Patrick Saulnier, Bastien Job, Marc Deloger, Marta Jimenez, Celine Mahier, Vianney Baris, Pierre Laplante, Patricia Kannouche, Virginie Marty, Magali Lacroix-Triki, Veronique Diéras, Fabrice André
The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2-drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd in patients with HER2-overexpressing (n = 72, cohort 1), HER2-low (n = 74, cohort 2) and HER2 non-expressing (n = 40, cohort 3) metastatic breast cancer. In the full analysis set population (n = 177), the confirmed objective response rate (primary endpoint) was 70...
July 24, 2023: Nature Medicine
Richard Adam, Kevin Dell'Aquila, Laura Hodges, Takouhie Maldjian, Tim Q Duong
Deep learning analysis of radiological images has the potential to improve diagnostic accuracy of breast cancer, ultimately leading to better patient outcomes. This paper systematically reviewed the current literature on deep learning detection of breast cancer based on magnetic resonance imaging (MRI). The literature search was performed from 2015 to Dec 31, 2022, using Pubmed. Other database included Semantic Scholar, ACM Digital Library, Google search, Google Scholar, and pre-print depositories (such as Research Square)...
July 24, 2023: Breast Cancer Research: BCR
Kristin Rojas, Laura M Spring, Liz O'Riordan, Anna Weiss
Breast cancer patients are living longer than ever before and as such the population of breast cancer survivors continues to grow. Approximately 80% of breast cancers are hormone receptor-positive (HR+) and most patients will receive neoadjuvant or adjuvant estrogen blockade, referred to as endocrine therapy. Although endocrine therapy reduces HR+ breast cancer recurrence by 30-50%, significant adverse effects pose a threat to treatment adherence. These adverse effects include vasomotor symptoms, colloquially referred to as hot flashes, bone loss, joint arthralgias, genitourinary syndrome of menopause (GSM), previously referred to as vaginal atrophy, and low libido...
July 26, 2023: Annals of Surgical Oncology
Naomi Dempsey, Ana Sandoval, Reshma Mahtani
Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2+), conferring a particularly aggressive subtype of the disease with an increased risk for the development of systemic and brain metastases. However, the advent of trastuzumab and more recently several other HER2-targeting novel therapies has led to significant improvements in the prognosis, making the diagnosis a "double-edged sword." The current standard first-line therapy for patients with HER2+ metastatic breast cancer (MBC) is a taxane combined with trastuzumab and pertuzumab...
September 2023: Current Treatment Options in Oncology
Robert M Pride, Charity C Glass, Faina Nakhlis, Alison Laws, Anna C Weiss, Jennifer R Bellon, Elizabeth A Mittendorf, Tari A King, Olga Kantor
BACKGROUND: Randomized trials have established the safety of observation or axillary radiation (AxRT) as an alternative to axillary lymph node dissection (ALND) in patients with limited nodal disease who undergo upfront surgery. Variability remains in axillary management strategies in cN0 patients undergoing mastectomy found to have one to two positive sentinel lymph nodes (SLNs). We examined the impact of intraoperative pathology assessment in axillary management in a national cohort of AMAROS-eligible mastectomy patients...
July 12, 2023: Annals of Surgical Oncology
Suneela Vegunta, Dawn M Mussallem, Aparna S Kaur, Sandhya Pruthi, Christine L Klassen
Atypical hyperplasia of the breast is a histopathologic lesion identified incidentally on image-guided breast biopsy. It is associated with a substantial increase in lifetime risk for breast cancer. Clinicians should counsel women with atypical hyperplasia regarding risk-reducing strategies, which include preventive endocrine therapy options, enhanced surveillance imaging, and lifestyle modifications. In this review, we describe 5 different but common clinical case scenarios for atypical hyperplasia of the breast and review management strategies for each scenario...
July 3, 2023: Cleveland Clinic Journal of Medicine
Giacomo Montagna, Mahmoud B El-Tamer
No abstract text is available yet for this article.
July 2, 2023: Annals of Surgical Oncology
Marija Balic, Christoph Thomssen, Michael Gnant, Nadia Harbeck
The St. Gallen Consensus Conference on early breast cancer treatment 2023 was again a live event and took place in Vienna, Austria. After 4 years and one virtual event due to the pandemic, more than 2,800 participants from over 100 countries came together in Vienna, and the 2023 St. Gallen/Vienna conference was a great success. Over 3 days, the global faculty reviewed the most important evidence published during the last 2 years and debated over controversial topics, and finally, the consensus votes aimed to define the impact of the new data on everyday routine practice...
April 2023: Breast Care
Benita S Katzenellenbogen, Valeria Sanabria Guillen, John A Katzenellenbogen
FOXM1 (Forkhead box M1) is an oncogenic transcription factor that is greatly upregulated in breast cancer and many other cancers where it promotes tumorigenesis, and cancer growth and progression. It is expressed in all subtypes of breast cancer and is the factor most associated with risk of poor patient survival, especially so in triple negative breast cancer (TNBC). Thus, new approaches to inhibiting FOXM1 and its activities, and combination therapies utilizing FOXM1 inhibitors in conjunction with known cancer drugs that work together synergistically, could improve cancer treatment outcomes...
June 27, 2023: Breast Cancer Research: BCR
Rebekah Law, Katherine Krupa, Jennifer Rusby
BACKGROUND: Breast Cancer incidence in the UK is estimated to rise to 71,000 per year by 2035. Preventative strategies could significantly reduce this. Preventative therapy reduces women's risk of oestrogen receptor positive breast cancer, but uptake remains low. Having established a preventative therapy clinic as part of a wider breast cancer prevention project, we explored qualitative data to inform future preventative efforts. METHOD: Women aged 30 to 60 who had benign diagnoses at a symptomatic breast clinic or were under mammographic surveillance in the moderate risk family history clinic were invited to participate in the study...
June 19, 2023: Breast Cancer Research and Treatment
2023-06-26 17:53:20
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.